Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.38 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9935890 | 0.86 | ACACB (0.50) | ACACBPARP1SLC5A1SLC5A2CACNA1H | |
| SCHEMBL24390647 | 0.86 | FLT3 (0.50) | ACACBMAPTKDM4EFLT3 | |
| SCHEMBL15268100 | 0.86 | ALDH1A1 (0.48) | ACACBALDH1A1HPGDSMN1; SMN2LMNA | |
| SCHEMBL16838854 | 0.85 | HPGD (0.52) | ACACBALDH1A1HPGDSMN1; SMN2LMNA | |
| SCHEMBL3753661 | 0.84 | ALDH1A1 (0.47) | ALDH1A1HPGDSMN1; SMN2LMNAMAPT | |
| SCHEMBL19105138 | 0.84 | CHRNB2 (0.43) | ACACBALDH1A1HPGDPARP1SLC5A1 | |
| SCHEMBL12170819 | 0.82 | ALDH1A1 (0.44) | ALDH1A1HPGDSMN1; SMN2LMNAMAPT | |
| SCHEMBL13704111 | 0.81 | ALDH1A1 (0.45) | ALDH1A1HPGDSMN1; SMN2LMNAMAPT | |
| SCHEMBL28371415 | 0.81 | ALDH1A1 (0.43) | ALDH1A1HPGDSMN1; SMN2LMNAMAPT | |
| SCHEMBL1299701 | 0.81 | HPGD (0.63) | ACACBALDH1A1HPGDSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298753-B1 | Novel oxetane compound, active energy ray-curable composition, active energy ray-curable ink composition and inkjet recording method | FUJIFILM CORP (JP) | 2015-07-08 | — | — | EP | disclosed |
| US-8222436-B2 | Oxetane compound, active energy ray-curable composition, active energy ray-curable ink composition and inkjet recording method | FUJIFILM CORPORATION (JP) | 2012-07-17 | — | — | US | disclosed |
| US-8222436-B2 | Oxetane compound, active energy ray-curable composition, active energy ray-curable ink composition and inkjet recording method | FUJIFILM CORPORATION (JP) | 2012-07-17 | — | — | US | disclosed |
| EP-2298753-A1 | Novel oxetane compound, active energy ray-curable composition, active energy ray-curable ink composition and inkjet recording method | Fujifilm Corporation (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-20110052831-A1 | NOVEL OXETANE COMPOUND, ACTIVE ENERGY RAY-CURABLE COMPOSITION, ACTIVE ENERGY RAY-CURABLE INK COMPOSITION AND INKJET RECORDING METHOD | FUJIFILM CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110052831-A1 | NOVEL OXETANE COMPOUND, ACTIVE ENERGY RAY-CURABLE COMPOSITION, ACTIVE ENERGY RAY-CURABLE INK COMPOSITION AND INKJET RECORDING METHOD | FUJIFILM CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052831-A1 | NOVEL OXETANE COMPOUND, ACTIVE ENERGY RAY-CURABLE COMPOSITION, ACTIVE ENERGY RAY-CURABLE INK COMPOSITION AND INKJET RECORDING METHOD | OXER1, NOX1, NOX4 | ACACB 2666/4885ALDH1A1 276/4885HPGD 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.